Protocol Ledger

NCT06731478 · Phase III · RECRUITING

Study of TDXd, Chemotherapy, Pembrolizumab, and Trastuzumab in First-Line Metastatic HER2-Positive Gastric or Gastroesophageal Junction Cancer

Interventional Phase III clinical trial protocol NCT06731478 sponsored by Daiichi Sankyo in Oncology and Hematology, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2025-02-27 Enrollment: 726 participants (ESTIMATED) Federal Source: clinicaltrials.gov/study/NCT06731478
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)726 participants (ESTIMATED)
Disclosed U.S. Hospital Campuses vs Median (6 sites)4 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT06731478
Protocol FieldVerified Registry Value
NCT IdentifierNCT06731478
Consolidated Lead SponsorDaiichi Sankyo
Therapeutic Condition CohortOncology and Hematology
Clinical Trial PhasePhase III
Overall Recruitment StatusRECRUITING
Registered Enrollment726 participants (ESTIMATED)
Registered Start Date2025-02-27
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Related Filings Across Meru Platforms

Verified cross-ledger federal filings for Daiichi Sankyo across sibling Meru public-data platforms.

Search related sites and sponsors in the Interactive Directory, explore Oncology and Hematology Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI